Maria Szarras-Czapnik

Maria Szarras-Czapnik

Auto-generated profile, based on publicly available information

Maria Szarras-Czapnik

Department of Endocrinology and Diabetology The Children's Memorial Health Institute Warsaw Poland

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
NKNils Krone
Nils Krone
NRNicole Reisch
Nicole Reisch
JIJan Idkowiak
Jan Idkowiak
VDVivek Dhir
Vivek Dhir
HIHannah E. Ivison
Hannah E. Ivison
WAWiebke Arlt
Wiebke Arlt
Context: P450 oxidoreductase deficiency (PORD) is a unique congenital adrenal hyperplasia variant that manifests with glucocorticoid deficiency, disordered sex development (DSD), and skeletal malformations. No comprehensive data on genotype-phenotype correlations in Caucasian patients are available. Objective: The objective of the study was to establish genotype-phenotype correlations in a large PORD cohort. Design: The design of the study was the clinical, biochemical, and genetic assessment including multiplex ligation-dependent probe amplification (MLPA) in 30 PORD patients from 11 countries. Results: We identified 23 P450 oxidoreductase (POR) mutations (14 novel) including an exonic deletion and a partial duplication detected by MLPA. Only 22% of unrelated patients carried homozygous POR mutations. p.A287P was the most common mutation (43% of unrelated alleles); no other hot spot was identified. Urinary steroid profiling showed characteristic PORD metabolomes with variable impairment of 17α-hydroxylase and 21-hydroxylase. Short cosyntropin testing revealed adrenal insufficiency in 89%. DSD was present in 15 of 18 46,XX and seven of 12 46,XY individuals. Homozygosity for p.A287P was invariably associated with 46,XX DSD but normal genitalia in 46,XY individuals. The majority of patients with mild to moderate skeletal malformations, assessed by a novel scoring system, were compound heterozygous for missense mutations, whereas nearly all patients with severe malformations carried a major loss-of-function defect on one of the affected alleles. Conclusions: We report clinical, biochemical, and genetic findings in a large PORD cohort and show that MLPA is a useful addition to POR mutation analysis. Homozygosity for the most frequent mutation in Caucasians, p.A287P, allows for prediction of genital phenotype and moderate malformations. Adrenal insufficiency is frequent, easily overlooked, but readily detected by cosyntropin testing.

1 November 2017 in Fertility and Sterility
Verified
Journal Article
Closed access
AHAngelica Lindén Hirschberg
Angelica Lindén Hirschberg
HGHedi Claahsen-Van der Grinten
Hedi Claahsen-Van der Grinten
NRNicole Reisch
Nicole Reisch
CBClaire Bouvattier
Claire Bouvattier
UTUte Thyen
Ute Thyen
MSMaria Szarras-Czapnik
Maria Szarras-Czapnik

17 November 2014 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
LOLaura O'HAra
Laura O'HAra
KMKerry McInnes
Kerry McInnes
ISIoannis Simitsidellis
Ioannis Simitsidellis
SMStephanie Morgan
Stephanie Morgan
NANina Atanassova
Nina Atanassova
LSLee B. Smith
Lee B. Smith
Leydig cell number and function decline as men age, and low testosterone is associated with all “Western” cardio‐metabolic disorders. However, whether perturbed androgen action within the adult Leydig cell lineage predisposes individuals to this late‐onset degeneration remains unknown. To address this, we generated a novel mouse model in which androgen receptor (AR) is ablated from ~75% of adult Leydig stem cell/cell progenitors, from fetal life onward (Leydig cell AR knockout mice), permitting interrogation of the specific roles of autocrine Leydig cell AR signaling through comparison to adjacent AR‐retaining Leydig cells, testes from littermate controls, and to human testes, including from patients with complete androgen insensitivity syndrome (CAIS). This revealed that autocrine AR signaling is dispensable for the attainment of final Leydig cell number but is essential for Leydig cell maturation and regulation of steroidogenic enzymes in adulthood. Furthermore, these studies reveal that autocrine AR signaling in Leydig cells protects against late‐onset degeneration of the seminiferous epithelium in mice and inhibits Leydig cell apoptosis in both adult mice and patients with CAIS, possibly via opposing aberrant estrogen signaling. We conclude that autocrine androgen action within Leydig cells is essential for the lifelong support of spermatogenesis and the development and lifelong health of Leydig cells.—O'Hara, L., McInnes, K., Simitsidellis, I., Morgan, S., Atanassova, N., Slowikowska‐Hilczer, J., Kula, K., Szarras‐Czapnik, M., Milne, L., Mitchell, R. T., Smith, L. B., Autocrine androgen action is essential for Leydig cell maturation and function, and protects against late‐onset Leydig cell apoptosis in both mice andmen. FASEB J. 29, 894–910 (2015). www.fasebj.org

5 April 2004 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
CSCedric Shackleton
Cedric Shackleton
JMJosep Marcos
Josep Marcos
EMEwa M. Malunowicz
Ewa M. Malunowicz
MSMaria Szarras‐Czapnik
Maria Szarras‐Czapnik
PJPetr Jira
Petr Jira
WAWiebke Arlt
Wiebke Arlt

18 August 2017 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
OGon behalf of the dsd-LIFE group
on behalf of the dsd-LIFE group
RRRobert Roehle
Robert Roehle
KGKatharina Gehrmann
Katharina Gehrmann
MSMaria Szarras-Czapnik
Maria Szarras-Czapnik
HGHedi Claahsen-Van der Grinten
Hedi Claahsen-Van der Grinten
BKBirgit Köhler
Birgit Köhler
Dsd-LIFE is a comprehensive cross-sectional clinical outcome study of individuals with disorders/differences of sex development (DSD). This study focuses on various rare genetic conditions characterized by impaired gonadal or adrenal functionality. The study aims to assess quality of life (QoL) as a measure of psychosocial adaptation, psychosexual and mental health aspects as major outcomes. Health status and functioning, medical and surgical therapies, participants’ views on health care, psychological and social support, sociodemographic factors and their interrelations will be investigated as factors associated with the outcomes. In addition, ethical considerations in the field of DSD are addressed and previous experiences with health care were gathered. One thousand and forty participants with different DSD conditions were recruited by 14 study centres in 6 European countries (France, Germany, the Netherlands, Poland, Sweden and the United Kingdom) from February 2014 until September 2015. The conditions included were: Turner syndrome (n = 301); 45,X0/46,XY conditions (n = 45); Klinefelter syndrome (n = 218); 47,XYY (n = 1); 46,XY gonadal dysgenesis/ovotestes (n = 63); complete androgen insensitivity (CAIS) (n = 71); partial androgen insensitivity (PAIS) (n = 35) and androgen synthesis disorders (n = 20); severe hypospadias (n = 25); other or non-classified 46,XY DSD (n = 8); 46,XX congenital adrenal hyperplasia (CAH) (n = 226); 46,XX gonadal dysgenesis/ovotestis (n = 21); and 46,XX in males (n = 6). For an add-on study, 121 46,XY male-assigned individuals with CAH due to 21-hydroxylase deficiency were recruited. Mean age of participants’ was 32.4 (+/− 13.6 years). Participation was high in conditions not commonly described as DSD, such as Turner and Klinefelter syndromes or CAH. Recruitment of individuals with XY DSD conditions proved to be more difficult. The data collection of PROs resulted in high data quality. Within medical and physical examination data, more missings and/or inaccurate data were found than expected. The European dsd-LIFE study recruited and evaluated the largest cross-sectional sample of individuals with different conditions classified under the term DSD. The data from this large sample will provide a sufficient basis for evidence-based recommendations for improvement of clinical care of individuals affected by a DSD condition. German Clinical Trials Register DRKS00006072 .

1 March 2018 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
MEM Engels
M Engels
KGK Gehrmann
K Gehrmann
Henrik FalhammarHenrik Falhammar
Henrik Falhammar
EWE A Webb
E A Webb
ANA Nordenström
A Nordenström
MSMaria Szarras-Czapnik
Maria Szarras-Czapnik
Context: Current knowledge on gonadal function in congenital adrenal hyperplasia (CAH) is mostly limited to single-center/country studies enrolling small patient numbers. Overall data indicate that gonadal function can be compromised in men with CAH.Objective: To determine gonadal function in men with CAH within the European ‘dsd-LIFE’ cohort.Design: Cross-sectional clinical outcome study, including retrospective data from medical records.Methods: Fourteen academic hospitals included 121 men with CAH aged 16–68 years. Main outcome measures were serum hormone concentrations, semen parameters and imaging data of the testes.Results: At the time of assessment, 14/69 patients had a serum testosterone concentration below the reference range; 7 of those were hypogonadotropic, 6 normogonadotropic and 1 hypergonadotropic. In contrast, among the patients with normal serum testosterone (55/69), 4 were hypogonadotropic, 44 normogonadotropic and 7 hypergonadotropic. The association of decreased testosterone with reduced gonadotropin concentrations (odds ratio (OR) = 12.8 (2.9–57.3)) was weaker than the association between serum androstenedione/testosterone ratio ≥1 and reduced gonadotropin concentrations (OR = 39.3 (2.1–732.4)). Evaluation of sperm quality revealed decreased sperm concentrations (15/39), motility (13/37) and abnormal morphology (4/28). Testicular adrenal rest tumor (TART)s were present in 39/80 patients, with a higher prevalence in patients with the most severe genotype (14/18) and in patients with increased current 17-hydroxyprogesterone 20/35) or androstenedione (12/18) serum concentrations. Forty-three children were fathered by 26/113 patients.Conclusions: Men with CAH have a high risk of developing hypothalamic-pituitary-gonadal disturbances and spermatogenic abnormalities. Regular assessment of endocrine gonadal function and imaging for TART development are recommended, in addition to measures for fertility protection.